Show simple item record

dc.contributor.authorKarimi, Y.en
dc.contributor.authorGhesquieres, H.en
dc.contributor.authorJurczak, W.en
dc.contributor.authorCheah, C.en
dc.contributor.authorClausen, M.en
dc.contributor.authorLugtenburg, P.en
dc.contributor.authorCunningham, D.en
dc.contributor.authorDo, Y. R.en
dc.contributor.authorLewis, D. J.en
dc.contributor.authorGasiorowski, R.en
dc.contributor.authorKim, T. M.en
dc.contributor.authorVan der Poel, M.en
dc.contributor.authorPoon, M. L. M.en
dc.contributor.authorFeldman, T. A.en
dc.contributor.authorLinton, Kim Men
dc.contributor.authorSureda, A.en
dc.contributor.authorHutchings, M.en
dc.contributor.authorStirner, M. C.en
dc.contributor.authorSacchi, M.en
dc.contributor.authorThieblemont, C.en
dc.date.accessioned2023-10-25T08:48:36Z
dc.date.available2023-10-25T08:48:36Z
dc.date.issued2023en
dc.identifier.citationKarimi Y, Ghesquieres H, Jurczak W, Cheah C, Clausen M, Lugtenburg P, et al. Effect of follow-up time on the ability of subcutaneous epcoritamab to induce deep and durable complete remissions in patients with relapsed/refractory large B-cell lymphoma: Updated results from the pivotal EPCORE NHL-1 trial. Journal of Clinical Oncology. 2023 Jun;41(16). PubMed PMID: WOS:001053772003468.en
dc.identifier.doi10.1200/JCO.2023.41.16_suppl.7525en
dc.identifier.urihttp://hdl.handle.net/10541/626652
dc.language.isoenen
dc.relation.urlhttps://dx.doi.org/10.1200/JCO.2023.41.16_suppl.7525en
dc.titleEffect of follow-up time on the ability of subcutaneous epcoritamab to induce deep and durable complete remissions in patients with relapsed/refractory large B-cell lymphoma: Updated results from the pivotal EPCORE NHL-1 trialen
dc.typeMeetings and Proceedingsen
dc.contributor.departmentUniversity of Michigan Comprehensive Cancer Center, Ann Arbor, MIen
dc.identifier.journalJournal of Clinical Oncologyen
dc.description.noteen]


This item appears in the following Collection(s)

Show simple item record